Oprelvekin

Interleukin 11 (IL 11) Recombinant CytokineRx: PrescriptionCompound: Approved

Also known as: IL-11, Neumega, recombinant human IL-11, rhIL-11

Educational Only — Not medical advice. Consult a qualified clinician before using any peptide.

Summary

Oprelvekin (recombinant IL-11) is a thrombopoietic growth factor approved to prevent severe thrombocytopenia and reduce the need for platelet transfusions following myelosuppressive chemotherapy in adults with nonmyeloid malignancies. It acts on megakaryocyte progenitors to boost platelet counts.

Mechanism of Action

Recombinant human interleukin-11 that directly stimulates proliferation of hematopoietic stem cells and megakaryocyte progenitor cells, and induces megakaryocyte maturation, resulting in increased platelet production.

Routes of Administration

Subcutaneous

Goals & Uses

  • Reduction of platelet transfusion needTransfusion MedicineHigh
  • Platelet count recoveryHematologyHigh
  • Prevention of severe thrombocytopenia after chemotherapyHematology / Oncology Supportive CareHigh

Contraindications

  • Congestive heart failureCardiovascularHigh
  • Hypersensitivity to oprelvekin or any componentAllergy / ImmunologyHigh
  • Myeloid malignanciesOncologyHigh
  • History of atrial arrhythmiasCardiovascularModerate

Adverse Effects

  • AnaphylaxisImmunologicRareSevere life-threatening allergic reaction
  • Injection site reactionsLocalCommon
  • HeadacheNeurologicCommonPain in the head or upper neck
  • Conjunctival injection / papilledemaOphthalmologicUncommon
  • Fluid retention / edemaFluid / ElectrolyteCommon
  • Atrial arrhythmias (flutter/fibrillation)CardiovascularUncommon

Drug Interactions

  • Antiarrhythmic agentsModerate
  • DiureticsModerateMay worsen dehydration or electrolyte imbalance

Population Constraints

  • PregnancyReproductive SafetyRelative
  • Renal impairmentOrgan ImpairmentRelative
  • Pediatric patientsAgeRelative
  • Elderly patientsAgeRelative

Regulatory Status

  • European UnionUnapprovedNever received EMA marketing authorization.
  • United StatesWithdrawnApproved: Prevention of severe thrombocytopenia following myelosuppressive chemotherapy in adults with nonmyeloid malignanciesApproved by FDA in 1997; voluntarily withdrawn from US market by Pfizer in 2012 for commercial reasons, not safety. No longer commercially available.
  • United KingdomUnapprovedNot approved by MHRA; not commercially available in the UK.

FDA approved in 1997 under the brand name Neumega. Withdrawn from the US market by Pfizer in 2012 due to commercial reasons, not safety concerns. Was never broadly approved outside the US.

Evidence & Sources

No sources recorded yet.

Browse All PeptidesBuild My Stack